CADL Key Statistics, Chart & Performance
The current stock price of CADL is 5.71 USD. In the past month the price decreased by -1.55%. In the past year, price decreased by -30.2%.
CADL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About CADL
Company Profile
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Company Info
CANDEL THERAPEUTICS INC
117 Kendrick Street,, Suite 450
Needham MASSACHUSETTS US
CEO: Paul Peter Tak
Employees: 38
Phone: 16179165445
CANDEL THERAPEUTICS INC / CADL FAQ
Can you describe the business of CANDEL THERAPEUTICS INC?
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Can you provide the latest stock price for CANDEL THERAPEUTICS INC?
The current stock price of CADL is 5.71 USD. The price increased by 2.88% in the last trading session.
Does CADL stock pay dividends?
CADL does not pay a dividend.
How is the ChartMill rating for CANDEL THERAPEUTICS INC?
CADL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CADL stock to perform?
14 analysts have analysed CADL and the average price target is 19 USD. This implies a price increase of 232.71% is expected in the next year compared to the current price of 5.71.
What is the next earnings date for CADL stock?
CANDEL THERAPEUTICS INC (CADL) will report earnings on 2026-03-23, after the market close.
Who owns CANDEL THERAPEUTICS INC?
You can find the ownership structure of CANDEL THERAPEUTICS INC (CADL) on the Ownership tab.
CADL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CADL. When comparing the yearly performance of all stocks, CADL is a bad performer in the overall market: 85.64% of all stocks are doing better.
CADL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CADL. The financial health of CADL is average, but there are quite some concerns on its profitability.
CADL Financial Highlights
Over the last trailing twelve months CADL reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 67.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.32% | ||
| ROE | -28.4% | ||
| Debt/Equity | 0.01 |
CADL Forecast & Estimates
14 analysts have analysed CADL and the average price target is 19 USD. This implies a price increase of 232.71% is expected in the next year compared to the current price of 5.71.